7-Epi-javaniside






Names

    • 7-Epi-javaniside

Attributes

  • Canonical SMILES

    C=C[C@H]1[C@@]2([H])C[C@@]3([H])[C@@]4(C5=CC=CC=C5NC4=O)CCN3C(C2=CO[C@@H]1O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)=O

  • InChI

    InChI=1S/C26H30N2O9/c1-2-12-13-9-18-26(15-5-3-4-6-16(15)27-25(26)34)7-8-28(18)22(33)14(13)11-35-23(12)37-24-21(32)20(31)19(30)17(10-29)36-24/h2-6,11-13,17-21,23-24,29-32H,1,7-10H2,(H,27,34)/t12-,13+,17+,18-,19+,20-,21+,23+,24-,26-/m0/s1

  • Molecule Class: Alkaloids
  • TPSA: 158.02
  • #RotBonds: 4
  • MW: 514.5310000000002
  • HBD: 5
  • HBA: 9
  • logP: -0.643799999999999
  • Chemical Formula: C26H30N2O9


Species

    Species Place of Collection NCBI Taxonomy Voucher Specimen
    T. divaricata China, Japan, Thailand, Bangladesh, Vienna 52861 BBP0671
    T. peduncularis Thailand 761087 WU 0099055

External Databases


References

  • Two Novel Iboga-Type and an Oxindole Glucuronide Alkaloid from Tabernaemontana peduncularis Disclose Related Biosynthetic Pathways to Tabernaemontana divaricata. Molecules, 2023 (PMID 37764440).

Compound-Protein Relationships

  • No relationship found

Compound Activities

    • Antiproliferative
    • Cytotoxicity

Predicted NMR Spectral Data


Predicted MS Fragmentation Pattern

    N.B.: It is recommended to zoom in on a specific area of an MS plot before hovering on a peak.

Predicted ADMET Properties

    Property Model Name Predicted Value
    Absorption Caco-2 (logPaap) -6.09
    Human Oral Bioavailability 20% Non-Bioavailable
    Human Intestinal Absorption Absorbed
    Madin-Darby Canine Kidney -5.06
    Human Oral Bioavailability 50% Non-Bioavailable
    P-Glycoprotein Inhibitor Non-Inhibitor
    P-Glycoprotein Substrate Substrate
    Skin Permeability 0.3
    Distribution Blood-Brain Barrier (Central Nervous System) -3.76
    Blood-Brain Barrier Penetrable
    Fraction Unbound (Human) 0.95
    Plasma Protein Binding 70.79
    Steady State Volume of Distribution 0.91
    Metabolism Breast Cancer Resistance Protein Non-Inhibitor
    CYP 1A2 Inhibitor Non-Inhibitor
    CYP 1A2 substrate Non-Substrate
    CYP 2C19 Inhibitor Non-Inhibitor
    CYP 2C19 substrate Non-Substrate
    CYP 2C9 Inhibitor Non-Inhibitor
    CYP 2C9 Substrate Non-Substrate
    CYP 2D6 Inhibitor Non-Inhibitor
    CYP 2D6 Substrate Non-Substrate
    CYP 3A4 Inhibitor Non-Inhibitor
    CYP 3A4 Substrate Substrate
    OATP1B1 Non-Inhibitor
    OATP1B3 Non-Inhibitor
    Excretion Clearance 5.43
    Organic Cation Transporter 2 Non-Inhibitor
    Half-Life of Drug Half-Life >= 3hs
    Toxicity AMES Mutagenesis Safe
    Avian Safe
    Bee Toxic
    Bioconcentration Factor -3.49
    Biodegradation Safe
    Carcinogenesis Safe
    Crustacean Safe
    Liver Injury I Safe
    Eye Corrosion Safe
    Eye irritation Safe
    Maximum Tolerated Dose 0.14
    Liver Injury II Toxic
    hERG Blockers Safe
    Daphnia Maga 4.76
    Micronucleos Toxic
    NR-AhR Safe
    NR-AR Safe
    NR-AR-LBD Safe
    NR-Aromatase Safe
    NR-ER Safe
    NR-ER-LBD Safe
    NR-GR Safe
    NR-PPAR-gamma Safe
    NR-TR Safe
    T. Pyriformis -2058.57
    Rat (Acute) 3.62
    Rat (Chronic Oral) 3.35
    Fathead Minnow 5.08
    Respiratory Disease Toxic
    Skin Sensitisation Safe
    SR-ATAD5 Toxic
    SR-ARE Safe
    SR-HSE Safe
    SR-MMP Safe
    SR-p53 Safe
    General Properties Boiling Point 511.43
    Hydration Free Energy -2.91
    Log(D) at pH=7.4 0.93
    Log(P) -0.92
    Log S -2.61
    Log(Vapor Pressure) -12.59
    Melting Point 208.05
    pKa Acid 4.27
    pKa Basic 5.72